South Africa Launches Patient-Led Cancer Registry

By Crystal Lubbe

March 4, 2025

Are we truly capturing the full landscape of cancer care in South Africa? South Africa has initiated a new approach to cancer data collection by introducing a patient-led cancer registry. This is in collaboration with the National Cancer Registry (NCR) and the non-governmental organization Living with Cancer South Africa. This initiative aims to fill data gaps and improve the accuracy of cancer statistics, which are currently limited by a pathology-based system that may miss diagnoses made outside laboratory settings.

Key Insights

Patients or their loved ones can now register cancer details online, providing a more comprehensive picture of cancer incidence in South Africa. The existing pathology-based system has been inadequate, particularly for cancers diagnosed through radiology, tumor markers, or clinical deduction rather than biopsies. Enhanced data will assist in better resource allocation and the development of data-driven cancer policies.  The new system also allows for recording historic cancer cases, including those of deceased individuals, to enrich the overall data.

Patient Cancer Registry

Established in 1986, the NCR has been the primary source of national cancer incidence data in South Africa. It uses a pathology-based surveillance system, which has limitations including heavy reliance on laboratory data and the potential to miss cases diagnosed through other methods. The use of both active and passive case-finding methods is crucial for improving the completeness and accuracy of cancer registry data. This is evidenced by other South African cancer registries like the Eastern Cape Cancer Registry. According to the World Health Organization, Africa faces a significant cancer burden, with around 1.1 million new cancer cases and 700,000 deaths annually. Accurate data collection through the patient-led cancer registry is essential for effectively addressing this crisis.

Health Implications

Improved cancer data will enable better resource allocation and more effective policy-making, enhancing cancer care and outcomes. This can optimize healthcare spending by targeting resources to areas with the highest need. Accurate and comprehensive data will aid in developing more targeted and effective cancer prevention and control strategies. Therefore, potentially leading to improved survival rates and better patient outcomes. Data-driven policies can be more effective in addressing the cancer burden. Involving patients in the reporting process ensures that policies are patient-centered and responsive to real-world needs.

By identifying and filling data gaps, South Africa can use its resources more efficiently. As a result, cancer care will become both accessible and effective across different regions and populations.

The patient-led cancer registry emphasises the importance of patient involvement in improving the accuracy and comprehensiveness of cancer data.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.